Back to results
US 12,606,604 B2Granted
Therapeutic compounds and methods
AssigneeRegents of the University of Minnesota
InventorsDaniel Attilio Vallera, Jeffrey S. Miller
Life of this patent
Estimating the term…
Abstract
This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
Claims18
A composition comprising:
- an NK engaging domain comprising an antibody or a binding fragment thereof;
- an NK activating domain comprising:
- the amino acid sequence of SEQ ID NO:15, or
- the amino acid sequence of SEQ ID NO:15 comprising an N72D amino acid substitution or an N72A amino acid substitution;
- a first linker linking the NK engaging domain to the NK activating domain, the first linker is selected from the group consisting of:
- SEQ ID NO:3;
- SEQ ID NO:4;
- amino acids 119-133 of SEQ ID NO:5;
- amino acids 494-518 of SEQ ID NO:8;
- amino acids 241-255 of SEQ ID NO:12;
- amino acids 488-506 of SEQ ID:10;
- amino acids 277-294 of SEQ ID NO:14;
- and
- amino acids 142-161 of SEQ ID NO:14;
- a targeting domain that selectively binds to a target antigen;
- and
- a second linker linking the NK activating domain to the targeting domain, the second linker is selected from the group consisting of:
- SEQ ID NO:3;
- SEQ ID NO:4;
- amino acids 119-133 of SEQ ID NO:5;
- amino acids 494-518 of SEQ ID NO:8;
- amino acids 241-255 of SEQ ID NO:12;
- amino acids 488-506 of SEQ ID:10;
- amino acids 277-294 of SEQ ID NO:14;
- and
- amino acids 142-161 of SEQ ID NO:14.
23 more elements
A composition comprising:
- an NK engaging domain comprising an anti-CD16 antibody;
- an NK activating domain comprising an IL-15, wherein the IL-15 comprises an amino acid sequence of SEQ ID NO:15, or an amino acid sequence of SEQ ID NO:15 comprising an N72D amino acid substitution or an N72A amino acid substitution;
- a first linker linking the NK engaging domain to the NK activating domain, the first linker comprising an amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4;
- a targeting domain comprising an anti-CD33 antibody or binding fragment thereof;
- and
- a second linker linking the NK activating domain to the targeting domain, the second linker comprising an amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4.
3 more elements
Dependencies are inferred from the claim text.